Related Experiment Video
Updated: Aug 23, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus
1Department of Medicine, Division of Rheumatology, Cedars-Sinai/UCLA School of Medicine, Los Angeles, USA. dwallace@ucla.edu
Abstract:
LJP 394 (abetimus, Riquent, La Jolla Pharmaceuticals) is four oligonucleotide B cell toleragen which acts as an 'anti-anti DNA'. Given as a weekly infusion, Phase 1, 2, and 3 studies with this biologic on close to 1,000 patients have demonstrated no toxicity of any note. In patients with lupus nephritis and an elevated anti-DNA (Farr assay) who have a high affinity to LJP 394, the drug significantly decreases anti-DNA, improves quality of life, and trends towards reducing renal flares. LJP 394 is a promising induction and/or maintenance therapy for lupus patients with elevated anti-DNA and active disease.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome I : Introduction
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease IV: Nursing Management
Chronic Kidney Disease IV: Nursing Management